Glatiramer Acetate Treatment in Multiple Sclerosis-Associated Fatigue—Beneficial Effects on Self-Assessment Scales But Not on Molecular Markers

Glatiramer Acetate Treatment in Multiple Sclerosis-Associated Fatigue—Beneficial Effects on Self-Assessment Scales But Not on Molecular Markers

Although fatigue is a common symptom in multiple sclerosis (MS), its pathomechanisms are incompletely understood. Glatiramer acetate (GA), an immunomodulatory agent approved for treatment of relapsing-remitting MS (RRMS), possesses unique mechanisms of action and has been shown to exhibit beneficial...

Full description

Bibliographic Details
Main Authors: Oliver Neuhaus, Wolfgang Köhler, Florian Then Bergh, Wolfgang Kristoferitsch, Jürgen Faiss, Thorsten Rosenkranz, Dirk Reske, Robert Patejdl, Hans-Peter Hartung, Uwe K. Zettl
Format: Article
Language:English
Published: MDPI AG 2021-03-01
Series:Biomolecules
Subjects:
multiple sclerosis
fatigue
glatiramer acetate
Online Access:https://www.mdpi.com/2218-273X/11/3/393

Internet

https://www.mdpi.com/2218-273X/11/3/393

Similar Items